PPD

Our team is on the ground at #ASCO26, showcasing our industry-leading capabilities along with our expertise in oncology clinical trials. Find us at booth 30131 and learn more about our commitment to precision oncology.

📢 Don't miss this upcoming free virtual event! If you've been thinking about joining us for The Science of Hiring: Data Science Edition, now is the time to lock in your seat. This event is your direct line to data science leaders at Thermo Fisher Scientific and the real stories behind the work they do in biotech, clinical research and life sciences. Whether you're early in your journey or a seasoned pro ready for your next move, this one's worth your hour. ✅ Live panel + interactive Q&A ✅ Real career paths and real projects Register now! 👉 http://spr.ly/6049B8bI3D #ScienceOfHiring #ThermoFisherCareers #LifeAtThermoFisher #DataScience

Rare immunology development presents distinct scientific and operational challenges that require a specialized approach. Success in rare immunology trials depends on deep therapeutic expertise, established site relationships and flexible, patient-centric delivery models. At a time when acceleration is essential, we're the right partner to advance your therapeutic development. We apply hands-on, global knowledge of medical and operational needs to quickly put your trial on the path to success. Learn more » http://spr.ly/6044B8bPoO

The path to success in biotech is personal and challenging, and every step matters. We aim to simplify the drug development journey with a comprehensive suite of biotech solutions, bringing expertise and efficiency to every phase, from pre-clinical research through commercialization. Our experts can accelerate your timeline, minimizing delays with efficient project management and execution. Discover how we help biotech companies move forward with confidence: http://spr.ly/6042B8ZF00

As the health care and life sciences landscape continues to evolve, organizations are facing increasing pressure to generate evidence faster and with more transparency, rigor and relevancy to real-world decision-making. In this month's edition of Pipeline to Patient, we’re highlighting new perspectives on the future of real-world evidence (RWE), including the launch of our new podcast series and additional insights into how biotech and biopharma organizations are leveraging real-world data and evidence to support smarter health care decisions across the product life cycle.

The current drug development landscape is defined by heightened uncertainty, rising costs, increasing trial complexity and a changing regulatory landscape — but there's also unprecedented opportunity. Based on our survey of 150 global biopharma and biotech leaders, here are 6️⃣ key trends and insights drug developers need to know to succeed in 2026.

There’s no one “right” way to approach biologics development, but some paths are undeniably more efficient than others. At Thermo Fisher Scientific, we know speed is a top priority for many sponsors bringing cutting-edge therapeutics to market. That’s why we’ve developed purpose-built capabilities, including Accelerator™ Drug Development, to help move you forward, faster. We’re excited to showcase the “how” behind these solutions at #BIO2026, taking place June 22-25 in San Diego. Visit us at booth 5125 or schedule a meeting. » http://spr.ly/6045B8nFBL

Precision medicine is changing the rules of patient identification, and many trial strategies haven’t caught up. Finding patients is no longer just about diagnosis. It’s about identifying the right patients based on biomarkers, molecular profiles and highly specific disease characteristics. And yet, one of the most critical enablers of that precision is often overlooked: the lab. In this new blog, we explore why patient identification is no longer just a recruitment challenge and how earlier lab integration can make or break a biomarker-driven study. Read more ⬇️

Are you attending #ERA26 in Glasgow, Scotland? Be sure to check out our e-poster, “Addressing Unmet Needs in Kidney Transplantation: Clinical Trial Trends in Delayed Graft Function and Antibody-Mediated Rejection," authored by experts Davide Garrisi, Sarah Dixon Stump, MS and Andy Bevan. Learn how we drive efficient and effective clinical trials that address the challenges associated with renal diseases. » http://spr.ly/6048B8u9u8

📊 Could your data skills help shape the future of healthcare and science? Join us for a free virtual event diving deep into data science careers across our global organization. ✅ Live panel + interactive Q&A ✅ Insight into real projects and career paths ✅ Direct access to hiring colleagues & leaders at Thermo Fisher Scientific Register now! 👉 https://lnkd.in/eAFs_4v4 #ScienceOfHiring #ThermoFisherCareers #LifeAtThermoFisher #DataScience